REGULATED INFORMATION – INSIDE INFORMATION 28 July 2020, 07:00 CEST Cash runway extended into H2 2021 enabling Sequana Medical to reach key near term value inflection points POSEIDON – implants resumed and interim results expected in Q1 2021 (North American pivotal study of the alfapump® in patients with recurrent or refractory ascites due to liver...Read More